Veracyte, Inc. (NASDAQ: VCYT) today announced that data from
five studies validating the performance of the next-generation
Afirma® Genomic Sequencing Classifier (GSC) in thyroid
cancer diagnosis will be presented at the 87th Annual Meeting of
the American Thyroid Association (ATA) being held October 18-22 in
Victoria, BC, Canada. Two oral and three poster presentations will
demonstrate the Afirma GSC’s ability to further reduce unnecessary
surgeries in thyroid cancer diagnosis while providing physicians
information to enable more appropriate treatment when suspicious
nodules are identified.
"We believe the results of these studies highlight the Afirma
GSC's unique ability to provide physicians with answers, including
answers to the most challenging biological questions, as they
evaluate patients for thyroid cancer," said Bonnie Anderson,
Veracyte's chairman and chief executive officer. "These data
reinforce our commitment to develop the extensive clinical evidence
required to gain both physicians' and patients' confidence in using
our genomic tests to inform important patient-care decisions."
Data from two studies evaluating the Afirma GSC's performance in
two of the most challenging thyroid biologies will be shared as
oral presentations at the ATA meeting:
Title:
Development and Validation of Classifiers
to Enhance the Afirma Genomic Sequencing Classifier Performance
Among Hürthle Cell Specimens (Short Call Oral Abstract #6)
Presenter:
Quan-Yang Duh, M.D., University of California, San Francisco
Date/Time:
Saturday, October 21, 8:50-9:50 a.m.*
Location:
Victoria Conference Center, Salon AB
Title:
Clinical Validation of the Afirma Genomic
Sequencing Classifier for Medullary Thyroid Cancer (Oral Abstract
#29)
Presenter:
Gregory Randolph, M.D., Massachusetts Eye
and Ear Infirmary
Date/Time:
Saturday, October 21, 3:20-4:50 p.m.
Location:
Victoria Conference Center, Salon AB
The following abstracts will be presented as posters:
Title:
Clinical Validation of the Afirma Genomic
Sequencing BRAF V600E Classifier (Poster 167)
Presenter:
Trevor E. Angell, M.D., Brigham and Women's Hospital
Date/Time:
Thursday, October 19, 9:50-10:45 a.m. and 3:05-4:00 p.m.
Location:
Victoria Conference Center, Crystal Garden ATA Exhibit Hall
Title:
Clinical Validation of the Afirma Genomic
Sequencing Parathyroid Classifier (Poster 168)
Presenter:
Julie Ann Sosa, M.D., Duke University
Date/Time:
Thursday, October 19, 9:50-10:45 a.m. and 3:05-4:00 p.m.
Location:
Victoria Conference Center, Crystal Garden ATA Exhibit Hall
Title:
Analytical Performance of Afirma GSC: A
Genomic Sequencing Classifier for Cytology-Indeterminate Thyroid
Nodule FNA Specimens (Short Call Poster 43)
Presenter:
Zhanzhi Hu, Ph.D., Veracyte, Inc.
Date/Time:
Friday, October 20, 9:50-10:45 a.m. and 3:05-4:00 p.m.
Location:
Victoria Conference Center, Crystal Garden ATA Exhibit Hall
* All Pacific Time
Veracyte also will host a Product Theater event, "The New
Afirma Genomic Sequencing Classifier – Leveraging Enriched Genomic
Data through RNA Sequencing and Advancements in Machine Learning to
Identify More Benign Thyroid Nodules," on Thursday, October 19,
3:05 p.m.– 4:00 p.m. Pacific Time in the Victoria Conference Center
Oak Bay Expo Theater.
About Afirma
The Afirma Genomic Sequencing Classifier is the next-generation
version of the Afirma Gene Expression Classifier, and is used to
identify patients with benign thyroid nodules among those with
indeterminate cytopathology results in order to preserve the
thyroid. Each year in the United States, more than 525,000 fine
needle aspiration biopsies are performed to assess patients with
potentially cancerous thyroid nodules. Up to 30 percent of the
results are indeterminate (not clearly benign or malignant) and
physicians have traditionally recommended thyroid surgery for a
more definitive diagnosis. Following surgery, however, 70 to 80
percent of patients' nodules are diagnosed as benign, meaning the
surgery was unnecessary. Such surgery is invasive, costly and often
leads to the need for lifelong daily thyroid hormone replacement
drugs.
About Veracyte
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company
that is providing trustworthy and actionable answers that
fundamentally improve patient care when current diagnostic tests
are uncertain. The company's products uniquely combine genomic
technology, clinical science and machine learning to provide
answers that give physicians and patients a clear path forward
without risky, costly surgery that is often unnecessary. Since its
founding in 2008, Veracyte has commercialized three genomic tests,
which are transforming the diagnosis of thyroid cancer, lung cancer
and idiopathic pulmonary fibrosis and collectively target a $2
billion market opportunity. Veracyte is based in South San
Francisco, California. For more information, please visit
www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "expect," "believe," "should,"
"may," "will" and similar references to future periods. Examples of
forward-looking statements include, among others, our belief that
our Afirma GSC's ability to further reduce unnecessary surgeries in
thyroid cancer diagnosis while providing physicians information to
enable more appropriate treatment when suspicious nodules are
identified, our beliefs with respect to the results of the studies,
including Afirma GSC's ability to provide answers to the most
challenging biological questions in evaluating patients, our
commitment to developing extensive clinical evidence required to
generate confidence in our products, and the applicability of
clinical results to actual outcomes. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans
and strategies, anticipated events and trends, the economy and
other future conditions. Forward-looking statements involve risks
and uncertainties, which could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: the applicability of clinical
results to actual outcomes; laws and regulations applicable to our
business, including potential regulation by the Food and Drug
Administration or other regulatory bodies; the ability of our
products to change treatment decisions and reduce unnecessary
surgeries; the occurrence and outcomes of clinical studies; the
timing and publication of clinical study results; and other risks
set forth in the company's filings with the Securities and
Exchange Commission, including the risks set forth in the company's
Quarterly Report on Form 10-Q for the quarter ended June 30,
2017. These forward-looking statements speak only as of the date
hereof and Veracyte specifically disclaims any obligation
to update these forward-looking statements.
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the
Afirma logo are trademarks of Veracyte, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171005005469/en/
Veracyte, Inc.Media:Tracy Morris,
650-380-4413tracy.morris@veracyte.comorInvestors:Jackie
Cossmon, 650-243-6371jackie@veracyte.com
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veracyte (NASDAQ:VCYT)
Historical Stock Chart
From Apr 2023 to Apr 2024